Coates P Toby H, Colvin Bridget L, Kaneko Katsuhiko, Taner Timucin, Thomson Angus W
Thomas E. Starzl Transplantation Institute and Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Transplantation. 2003 May 15;75(9 Suppl):32S-36S. doi: 10.1097/01.TP.0000067949.90241.CB.
There are various approaches to the enhancement of dendritic cell (DC) tolerogenicity for the promotion of cell or organ allograft survival. Both pharmacologic and biologic agents, including several commonly used immunosuppressive drugs, and specific anti-inflammatory cytokines inhibit DC maturation, whereas co-stimulation-blocking agents can also promote the induction of antigen-specific T-cell unresponsiveness by DC. Delivery of genes encoding molecules that subvert T-cell responses by various mechanisms, and targeting of DC migration by selective manipulation of chemokine and chemokine receptor expression, represent additional promising strategies. In this short review, the authors consider those approaches that have been used to promote the tolerogenicity of donor-derived DC in experimental models. Whereas most work to date has focused on myeloid DC, manipulation of other DC subsets may also offer potential for improving the outcome of transplantation and enhancing tolerance induction.
有多种方法可增强树突状细胞（DC）的致耐受性，以促进细胞或器官同种异体移植的存活。包括几种常用免疫抑制药物在内的药理和生物制剂，以及特定的抗炎细胞因子均可抑制DC成熟，而共刺激阻断剂也可促进DC诱导抗原特异性T细胞无反应性。通过各种机制递送编码破坏T细胞反应分子的基因，以及通过选择性操纵趋化因子和趋化因子受体表达来靶向DC迁移，是另外一些有前景的策略。在这篇简短综述中，作者探讨了在实验模型中用于促进供体来源DC致耐受性的那些方法。尽管迄今为止大多数研究都集中在髓样DC上，但对其他DC亚群的操控也可能为改善移植结果和增强耐受性诱导提供潜力。
